A detailed history of Dimensional Fund Advisors LP transactions in I Mab stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 60,407 shares of IMAB stock, worth $95,443. This represents 0.0% of its overall portfolio holdings.

Number of Shares
60,407
Previous 36,123 67.23%
Holding current value
$95,443
Previous $68,000 64.71%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$1.54 - $2.37 $37,397 - $57,553
24,284 Added 67.23%
60,407 $112,000
Q2 2023

Aug 09, 2023

SELL
$2.95 - $3.85 $22,980 - $29,991
-7,790 Reduced 17.74%
36,123 $108,000
Q1 2023

May 12, 2023

SELL
$3.08 - $7.39 $11,309 - $27,136
-3,672 Reduced 7.72%
43,913 $151,000
Q4 2022

Feb 09, 2023

SELL
$3.22 - $4.86 $2,743 - $4,140
-852 Reduced 1.76%
47,585 $198,000
Q3 2022

Nov 10, 2022

BUY
$4.01 - $12.34 $194,232 - $597,712
48,437 New
48,437 $194,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $131M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.